← board
NCEL
distress 6/10 · elevated risk$3.70+1%today-87% from 52w high
Revenue
pre-revenue
Liquidity
$2M
Runway
0.8 yrs
Shares 1y
0%
Price & events
+39.1% over 6M
CatalystRating changeDilutionFinancingdashed = today
+1.4%
1D
-5.4%
1W
+4.5%
1M
-24.6%
3M
+38.6%
6M
-83.2%
1Y
-95.2%
2Y
-99.7%
5Y
-99.7%
All
Overview
- Market Cap
- $17.75M
- Volume
- 5.41K
- 52 Week Range
- $1.88 – $27.90
- Total Shares
- 4.80M
- Float Shares
- 2.61M
- Short %
- 1.90%
- % Held by Insiders
- 68.06%
- % Held by Institutions
- 1.14%
- RVOL
- 0.19x
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $23 (+522% upside) · 1 analysts
- 2026-07-13Laidlaw & Co.Buy
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.